Latest news with #GoodRx
Globe and Mail
4 days ago
- Business
- Globe and Mail
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc.
The law firm of Kahn Swick & Foti, LLC ('KSF') has commenced an investigation into GoodRx Holdings, Inc. (NasdaqGS: GDRX) ('GoodRx'). KSF is investigating whether GoodRx's officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of GoodRx Holdings, Inc. (Nasdaq: GDRX), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
Newsweek
6 days ago
- Health
- Newsweek
80% of US Counties Contain 'Health Care Deserts': Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A growing number of Americans find themselves living in "health care deserts," areas lacking in the specific infrastructure and services needed to ensure timely access to medicine and care, new data suggests. According to new research from health care and prescription price-comparison website GoodRx, 81 percent of U.S. counties—home to more than 120 million Americans—fall under this definition in some way. This includes those which lack proper access to either pharmacies, primary care, hospital beds, trauma centers or community health centers. Why It Matters As a result of large-scale drugstore closures this year, 2025 has already been marked by a rise in so-called "pharmacy deserts," with more Americans having to travel further from where they live to access essential medications. The broader term used by GoodRx denotes a more pervasive issue, one which it says threatens not only the availability of medicine but also vital services needed in times of emergency. Covenant Children's Hospital on February 28, 205 in Lubbock, Texas. Covenant Children's Hospital on February 28, 205 in Lubbock, issues with physically accessing health care are in addition to those associated with cost, as health care continues to prove prohibitively expensive for a significant number of Americans. What To Know According to the GoodRx data, as well as the 81 percent of counties experiencing a health care desert of some kind, a majority of people in 60 percent of counties lack adequate access to more than one form of critical health service. Certain states, the research suggests, are more exposed to these issues, with 87 percent of those in Wyoming, 74 percent of those in Vermont and 70 percent of Montanans living in a health care desert county. Amanda Nguyen, Senior Health Economist at GoodRx, told Newsweek the prevalence of health care deserts was driven "by structural gaps and shifting policies." Nguyen said certain areas had lost their federal shortage designations—which agencies use to help direct federal funding and other forms of assistance—despite the fact that health care access has not improved. She added that health care deserts were particularly common in rural and lower-income communities with high uninsured rates. This, she said, "creates a negative cycle—as more people struggle to pay for care, hospitals and pharmacies are more likely to close, further eroding access." A woman browses through what items remain on empty shelves at a Rite Aid store in Alhambra, California, on October 18, 2023. A woman browses through what items remain on empty shelves at a Rite Aid store in Alhambra, California, on October 18, 2023. Frederic J. Brown/AFP via Getty Images Since its previous research into the topic, GoodRx said pharmacy deserts had seen the largest increase, with 48 million people now living in such areas, up from 41 million in 2021. In the U.S. today, 45 percent of counties can be classified as pharmacy deserts, GoodRx added, noting this was especially concerning given nationwide medication shortages. Emergency medical care also remains out of reach a significant number of Americans, the study suggests. GoodRx found that more than 28 million people live half an hour from the nearest hospital, nearly 50 million live over an hour from a facility able to handle major injuries, and 79 million are in areas with fewer than two hospital beds per 1,000 people. What People Are Saying Amanda Nguyen, Senior Health Economist at GoodRx, told Newsweek: "When care is far away or hard to afford, people may delay or skip care altogether. And that can have serious consequences. Our research found that nearly 1 in 5 Americans had to visit multiple pharmacies just to get their medication — and that's in areas with some access. Now imagine that same challenge in a county with no nearby pharmacy, hospital, or primary care provider. These delays and gaps add up, especially for people managing chronic conditions or without insurance." Tori Marsh, Senior Director of Research at GoodRx, discussing the issue of pharmacy closures and deserts with Newsweek previously, said: "Many of the counties hardest hit by pharmacy closures already had limited access. Now, they're losing their last remaining pharmacies, creating health care deserts with no immediate solutions in place." What Happens Next? Pharmacy closures are set to continue through 2025, as major chains such as CVS and Rite Aid scale down their nationwide footprint.
Yahoo
7 days ago
- Business
- Yahoo
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
New cash pay program offers Contrave, the #1 branded oral non-GLP-1 weight loss medication brand, for as low as $199 per month* BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance. According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment. "At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health." Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles. "Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication." Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity. For more information or to access the GoodRx Contrave savings card, visit: *Program benefit maximums and eligibility restrictions may apply. About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit About CONTRAVE: CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to Media Contactcurrax@ View original content to download multimedia: SOURCE Currax Pharmaceuticals LLC Melden Sie sich an, um Ihr Portfolio aufzurufen.
Miami Herald
14-07-2025
- Health
- Miami Herald
More Americans than ever are struggling to afford their prescriptions
For millions of Americans, affording prescription medications is getting harder, not easier. According to new survey data from GoodRx, a platform for medication savings, people are more likely than ever to view their prescriptions as a financial burden. More people are skipping doses, cutting back on essentials, or turning to creative - and sometimes risky - workarounds to continue their prescribed treatment. Key takeaways: According to the GoodRx Research survey, 67% of Americans who filled a prescription described the cost of their medication as a for prescription drugs leads many Americans to make sacrifices in other areas of life. Almost 30% of people reported cutting back on spending for food or clothing to pay for their out-of-pocket costs change how people take their medications. Among people who filled a prescription in 2025, 1 in 5 reported rationing their medications due to cost. Most Americans continue to feel the financial burden of prescriptions GoodRx Research surveyed over 1,000 people who filled a prescription in 2025 about their healthcare expenses. Here's how they described their out-of-pocket cost for medications: Minor burden: 35% (up from 30.9% in 2024)Moderate burden: 21%Significant burden: 10%Catastrophic burden: 2%Not a burden: 33% (down from 35.8% in 2024) In other words, over 67% of Americans who filled a prescription said their out-of-pocket cost was at least a minor financial burden. Prescription drugs remain one of many competing priorities in Americans' budgets. For many, medication costs now rank higher than concerns about housing, food, and transportation. In 2025, 38% of people said they worried about being able to afford their medications, up significantly from 27% in 2024. More than half (57%) worried about affording at least one healthcare or essential cost in the past year. Even though prices for medical care and medications have increased more slowly than other categories of spending, Americans are still struggling to afford their prescriptions. Americans are still making sacrifices to pay for prescriptions In 2024, 37% of Americans reported taking action that could negatively impact their lifestyle or personal finances. And the pinch is getting worse. In 2025, that number went up to 46%. Lifestyle sacrifices were common: 29% cut spending on leisure activities (up from 23% in 2024)28% reduced spending on food or clothing (a sharp increase from 16% in 2024)16% dipped into savings to cover the cost of treatment9% sold personal belongings to help pay for medications15% adjusted their or a family member's employment, either by working more hours or taking on an additional job In addition to lifestyle changes, many Americans took on direct financial burdens to cover healthcare expenses. In 2025, 42% reported taking some kind of financial action due to healthcare costs, up from 39% in 2024. Here are some financial actions people took: 25% took on credit card debt (up from 22% in 2024)18% borrowed money from friends or family6% took out a loan (up from 4% in 2024) These tradeoffs - both lifestyle and financial - highlight the growing challenges many Americans face in accessing and taking their prescribed treatments. Cost continues to affect medication adherence Cost pressures are changing how Americans take their medications. In 2024, 34% of people reported making at least one change to how they managed their prescriptions due to cost. By 2025, that number went up to 42%. This includes: 16% who delayed refills (down slightly from 17%)20% who rationed their medications (up from 15%)13% who stopped taking a medication entirely (up from 8%) These changes, while often financially motivated, can carry serious health consequences - especially for those managing chronic or life-threatening conditions. The rise in these behaviors signals growing pressure on patients as they try to balance their health needs with financial realities. People are getting creative to afford their medication When prescriptions are too expensive, people may take steps to make sure they can get their medications. In 2025, 75% used at least one nontraditional resource, up from 70% in 2024. Discount programs were among the most common tools, used by 43% of respondents, and 40% received free samples directly from their clinician. Many also shopped around at different pharmacies or asked their healthcare professional for more affordable alternatives. Others turned to manufacturer copay cards or low-income subsidy programs to reduce their out-of-pocket costs. These strategies reflect a growing willingness to find creative solutions in the face of rising prices. Some people took riskier measures: 12.9% replaced prescriptions with over-the-counter medications or supplements9.5% used medications prescribed to someone else5.9% purchased medications from another country Overall, more than a third of Americans (38%) said they used a prescription discount card or coupon this year - highlighting the importance of accessible pricing tools outside the traditional insurance model. The bottom line Prescription medications remain a financial burden for most Americans. Peterson-KFF Health System Tracker reported in 2024 that almost 1 in 12 Americans have medical debt, with the cost of prescription medications contributing to the problem. In the face of unaffordable medications, many Americans are taking their healthcare into their own hands. They are seeking out discount programs, using manufacturer copay cards, and talking to their healthcare professional about the cost of care. Expanding these resources is an important first step to improving medication access and affordability. This story was produced by GoodRx and reviewed and distributed by Stacker. © Stacker Media, LLC.
Politico
11-07-2025
- Business
- Politico
Investor visa firm lobbies up
With Daniel Lippman IMMIGRATION FIRM HIRES GREENBERG: A Florida-based company that helps foreign investors secure permanent residency in the U.S. under a program potentially under threat from President Donald Trump's 'gold card' visa proposal has brought on new lobbying help. — According to a newly filed disclosure, U.S. Immigration Fund retained Laura Reiff of Greenberg Traurig last month to lobby on issues related to the EB-5 program, which grants conditional green cards to foreigners who invest in qualifying businesses like real estate projects that create new jobs in the U.S. USIF acts as a broker for EB-5 visas by connecting businesses with foreign investors, but the so-called gold card program proposed by Trump earlier this year has been eyed to replace the EB-5 program, which already faces an extensive backlog. — The White House last month rolled out sign-ups to get on a waiting list for the gold cards, under which wealthy foreigners could write a $5 million check and immediately receive permanent residency in the U.S. — But a March op-ed from Nicholas Mastroianni III, USIF's president, warned that the gold card proposal still 'lacks legal foundation, legislative approval, and economic impact considerations' compared to EB-5, which Mastroianni said cannot be unilaterally eliminated and thus 'remains a well-established, structured, and legally protected program' for foreign investors amid the Trump administration's immigration crackdowns. MORE NEW BUSINESS: Private security firm Allied Universal has brought on a pair of new outside firms to lobby on a panoply of issues, including security for military installations and federal facilities, FEMA coordination and disaster zone planning, next year's World Cup and Olympics and U.S. trade negotiations with India and South Africa. Allied retained Cornerstone Government Affairs back in May, according to a newly filed disclosure, and Cornerstone brought on JGB & Associates' John Buscher as a subcontractor to work on the account. — Software giant Oracle has hired Caroline Canfield, a former staff director for the Senate Veterans' Affairs Committee, to work on VA issues as the Trump administration pushes for more funding to accelerate its electronic health record modernization, which is being replaced with Oracle's service. — And yet another newly filed disclosure revealed that prescription-drug discount provider GoodRx has continued to add to its lobbying bench. Capitol Hill Consulting Group began working for the platform back in May on issues related to lowering prescription drug costs — the third new outside firm signed by GoodRx between May and June. Happy Thursday and welcome to PI. Send lobbying tips: Add me on Signal at caitlinoprysko.17, email me at coprysko@ and be sure to follow me on X: @caitlinoprysko. THE STATE OF THE SWAMP IS STRONG: The second Trump administration has ushered in a new wave of opportunity for the influence industry, anointing a new crowd of power brokers who aren't shy about declaring an end to the K Street of yesteryear, as pair of new stories in New York Magazine and The Wall Street Journal lays out. — That includes Ches McDowell of Checkmate Government Relations, who told NY Mag's Ben Terris that his firm expected to pull in around $5 million in revenues in the second quarter. 'November 4 was the day K Street died,' McDowell told NY Mag. 'The lobby firms' old relationships don't work anymore.' — And some lobbyists are trying to accelerate that dynamic, with one Republican touting a dossier outlining the 'hypocrisy' of top trade association honchos who criticized Trump following the Jan. 6, 2021 attack on the Capitol but who are now trying to buddy up to the president. — And then of course there's the world of more shadowy influence campaigns, which has seen MAGA influencers reportedly paid to shill for the soda industry, PR veterans work to place hit pieces in outlets like Breitbart and lawyers, lobbyists and everyone in between scrambling to cash in on the effort to score a presidential pardon, as well as the class of consultants close to the president who aren't required to disclose any details of their work. — But 'beneath the bonanza,' the Journal's Josh Dawsey, Rebecca Ballhaus and Maggie Severns write, 'lobbyists know the clock is ticking. While the Trump administration has retreated from investigating the types of cases that have gotten lobbyists into trouble in the past, Democratic scrutiny could come as early as 2027 if the party retakes the House next year. When Democrats secured the House majority midway though Trump's first term, they mounted investigations into Trump and his aides, including two impeachment inquiries.' — 'That possibility leaves a narrow window to cash in on ties to the administration—but not so much that it attracts unwanted attention when the tides shift, some lobbyists said. Several described a sweet spot of making $3 million to $5 million a year, but staying off the radar.' IF YOU MISSED IT WEDNESDAY: The U.S. Chamber of Commerce and Consumer Technology Association have waded into the legal battle over Trump's tariff authority, urging a federal appeals court yesterday to strike down the 1977 emergency powers law underpinning the administration's 10 percent baseline tariff and threats of so-called reciprocal tariffs on dozens of U.S. trading partners. — 'Trump's use of the International Emergency Economic Powers Act 'to impose virtually unbounded tariffs is not only unprecedented, but is causing irreparable harm to [our] members and to small businesses in particular, increasing their costs, undermining their ability to plan for the future, and in some cases threatening their very existence,' the business groups wrote in the amicus brief, also known as a 'friend of the court' brief, in a combined set of lawsuits brought by a group of small businesses and a dozen Democratic states,' POLITICO's Doug Palmer reports. — While trade associations like the Chamber and CTA have not been shy about their opposition to Trump's tariffs, thus far major business lobbies have been content to leave the legal challenges of his authority to impose them to small businesses and Democratic attorneys general, reluctant to stick their necks out and risk provoking Trump's ire. PI wonders if that will begin to change after notching the permanent extension of beloved industry tax breaks in last week's reconciliation bill. ANNALS OF CAMPAIGN FINANCE: Elon Musk 'has not yet officially established the 'America Party,' the idea for which he announced this weekend,' but Dave Levinthal writes for OpenSecrets that 'a number of jokers, wags and potential fraudsters have rushed to fill that vacuum, filing paperwork with federal regulators claiming the America Party mantle — and prompting officials at the Federal Election Commission to fire off a volley of legal warnings.' — 'So far, at least 10 separate political committees bearing some variation of the 'America Party' name have been registered with the FEC since Musk's announcement, an OpenSecrets review of federal records indicates. Several more, such as 'The DOGE Party' and an 'Elon Reeve Musk' congressional committee in Texas, play on Musk's name or history.' — In a letter to one such group claiming to be headquartered in a California city in which Musk's Tesla has a facility and that Tesla's CFO is the group's treasurer, FEC senior campaign finance analyst Jacqueline Gausepohl warned that 'it has come to the attention of the Federal Election Commission that you may have failed to include the true, correct, or complete committee information,' and that lying to a federal agency is against federal law. — Newly formed party committees such as The America Party Committee, US American Party and American Meme Party also found themselves on the receiving end of FEC warnings this week. But 'while the FEC is indeed talking tough, the agency also finds itself in the midst of a de facto shutdown' that bars it from taking any real action, Levinthal notes. FIRST IN PI — HOLLYWOOD BACKS SEMIQUIN: The Motion Picture Association has partnered with the organization spearheading America's 250th birthday celebration over the next year. 'America is the birthplace and home of the film and television industry – a country where the creative sector serves as a backbone of our economic strength, our cultural power, and our global leadership,' Charles Rivkin, MPA's chair and CEO, said in a statement. — The partnership has already kicked off with new signage featuring the America250 logo and the logos of MPA's member studios outside the trade association's headquarters just a block from the White House, and will include additional programming over the next year touting 'the motion picture industry's cultural and economic impact' in the U.S. — MPA is the latest industry player to team up with America250, the nonprofit group organizing the semiquincentennial celebration. Though the festivities, which are publicly funded, are officially nonpartisan, Mother Jones highlighted last month how America250 'has seen an influx of MAGA loyalists.' — The celebrations have already attracted a flood of corporate support — including from companies with ties to the president, like UFC, Oracle and Palantir — or who have policy priorities in front of the government, including Coinbase, Amazon, Walmart, Chrysler-Dodge-Jeep-Ram, Coca-Cola and Lockheed Martin. NEXT ON CONSERVATIVES' WISHLIST: 'Fresh off passage of the 'One Big Beautiful Bill,' several conservative organizations and Republican lawmakers are preparing to ask President Donald Trump for another major tax cut — this time, potentially without congressional approval,' according to The Washington Post's Jeff Stein. — The coalition, which includes the anti-tax Americans for Tax Reform, is 'already asking the Trump administration to get behind another cut' to slash investors' capital gains taxes by tweaking how they're calculated by the Treasury Department. — 'Under the proposal pitched by [ATR founder Grover] Norquist and others, the calculation would start by adjusting up the value of the original purchase to account for inflation — which would reduce the amount of gain that's taxable after selling the stock.' — 'Although a 1992 Justice Department opinion found that such a change would require an act of Congress, Norquist and other conservatives want the Treasury Department to execute such a policy unilaterally if necessary, providing a major windfall for people selling stocks, art, businesses, homes and other assets.' Jobs report — Vanessa Le has joined Latham & Watkins as a partner in the white collar defense and investigations practice and as a member of the litigation and trial department. She was most recently of counsel for national security and global trade at DLA Piper and is a Biden White House, DNI and Senate Intelligence Committee alum. — Meridian International Center has added Jim Golsen as vice president of the Center for Corporate Diplomacy and Kellee Wicker as vice president of the Center for Technology, Innovation, and Space. Golsen previously was deputy director general at the Commerce Department. Wicker previously was director of the science and technology innovation program at the Wilson Center. — Dexter Hendricks is the Coalition For Community Solar Access' new senior manager of interconnection policy, Morning Energy reports. He previously was a technology manager at the Department of Energy's Solar Energy Technologies Office. New PACs Bridge Political Action Committee (Super PAC) JOHN MORGAN FOR GOVERNOR (Super PAC) Run with Pride PAC (PAC) STOP LIBERAL REPUBLICANS PAC (Super PAC) TENNESSEE FIGHTER PAC (Super PAC) New Lobbying REGISTRATIONS Ark Strategy: Overwatch Imaging, Inc. Ballard Partners: Ambipar Holding USa Canfield Consulting, LLC: Novacoast Federal Inc. Capitol Advocacy & Government Affairs, LLC: Sensus Healthcare, Inc. Capitol Hill Consulting Group: Cedars Sinai Capitol Hill Consulting Group: Goodrx, Inc Grant Consulting Group: Manny Lentine, Inc. Greenberg Traurig, LLP: US Immigration Fund Holland & Knight LLP: Bioprincipia Holland & Knight LLP: Tiverton Advisors, LLC J.A. Green And Company (Formerly LLC): Albion Platform Holdings LLC J.A. Green And Company (Formerly LLC): Avio USa Leolabs, Inc.: Leolabs, Inc. Mindset Advocacy, LLC: Readycap Lending LLC Powers Pyles Sutter & Verville, P.C.: Stellar Health Puentes Global Advisory LLC: Central American Bank For Economic Integration (Cabei) Sandler, Travis & Rosenberg, P.A.: Beacon Wellness Brands Smith Garson Fka Smith Dawson & Andrews: Sunline Transit Agency Stinson LLP: Gtgrocs, LLC The Roosevelt Group: Valiant Strategies Obo R.R.P. Consulting Engineers Obo Southwebb Bridge Company Vial Health Technology, Inc.: Vial Health Technology, Inc. Williams And Jensen, Pllc: Ixpressgenes New Lobbying Terminations A1.9 Strategies LLC: Intact Technology Adomi Advisory Group Pllc: Dr. Shallfdeen Amuwo Cgcn Group, LLC: American Free Enterprise Chamber Of Commerce Daly Consulting Group: American Free Enterprise Chamber Of Commerce Dentons US LLP: American Association Of International Healthcare Recruitment Focus Dc LLC: Interactions LLC Focus Dc LLC: The Nuclear Company Gonring, Spahn & Associates, Inc.: 2U, Inc Gonring, Spahn & Associates, Inc.: At&T Services, Inc. Grant Consulting Group: Raymond James Insurance Group Inc Holland & Knight LLP: Clark Street Associates On Behalf Of Pacific Fusion Corporation Holland & Knight LLP: Exowatt, Inc. Miller Strategies, LLC: American Free Enterprise Chamber Of Commerce Mr. Gaylord Kent Conrad: Molina Healthcare, Inc. O'Keeffe Shahmoradi Strategies, LLC: Commercial Vehicle Training Association Peter Damon Group LLC: State Federal Strategies On Behalf Of Tc Energy Polsinelli Pc: Elekta Inc. Valiant Public Affairs: Cross Oil Refining & Marketing, Inc.
